Prime Medicine (PRME) Income Statement (2021 - 2026)
Income Statement report data from Mar 31, 2021 to Mar 31, 2026 for Prime Medicine (PRME).
All data is split-adjusted. You can find the most accurate data from the reports on the SEC official website. We recommend verify information using official company filings before making investment decisions.
Reported currency: USD
| Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Mar 31, 2021 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue and COGS | ||||||||||||||||||||
Total Revenue | - | 840K (-31.71%) | 1.23M (+9.82%) | 1.12M (-22.76%) | 1.45M (-33.49%) | 2.18M (+938.10%) | 210K | - | 590K | - | - | - | - | - | - | - | - | - | - | - |
Operating Expenses | ||||||||||||||||||||
Research And Development | 34M (-1.76%) | 35M (-21.10%) | 44M (+6.31%) | 41M (+2.02%) | 41M (+18.94%) | 34M (-15.47%) | 40M (-6.34%) | 43M (+14.03%) | 38M (-8.90%) | 41M (+1.20%) | 41M (+18.41%) | 35M (+12.05%) | 31M (-35.67%) | 48M (+91.62%) | 25M | - | 14M (-78.34%) | 63M (+753.38%) | 7.40M | - |
Selling General And Administrative | 17M (+18.11%) | 15M (+31.49%) | 11M (-14.56%) | 13M (-1.20%) | 13M (+7.97%) | 12M (-12.77%) | 14M (+11.90%) | 13M (+12.90%) | 11M (-14.68%) | 13M (+24.69%) | 10M (-1.59%) | 11M (+16.50%) | 9.15M (-4.98%) | 9.63M (+45.69%) | 6.61M (-10.31%) | 7.37M (+18.49%) | 6.22M (-42.94%) | 11M (+259.74%) | 3.03M | - |
Operating Expenses | 52M (+4.17%) | 49M (-10.42%) | 55M (+1.30%) | 54M (+1.19%) | 54M (+16.03%) | 46M (-14.75%) | 54M (-2.21%) | 56M (+13.77%) | 49M (-28.09%) | 68M (+32.22%) | 51M (+13.70%) | 45M (+13.07%) | 40M (+3.46%) | 39M (+22.20%) | 32M (+20.33%) | 26M (+32.21%) | 20M (-73.13%) | 74M (+609.97%) | 10M | - |
Depreciation And Amortization | 1.86M (-1.06%) | 1.88M (0.00%) | 1.88M (+1.08%) | 1.86M (+9.41%) | 1.70M (-1.16%) | 1.72M (+10.26%) | 1.56M (+1.30%) | 1.54M (+16.67%) | 1.32M (+5.60%) | 1.25M (+0.81%) | 1.24M (+10.71%) | 1.12M (+6.67%) | 1.05M (+20.69%) | 870K (+38.10%) | 630K (+46.51%) | 430K (+48.28%) | 290K (-21.62%) | 370K (+85.00%) | 200K | - |
Operating Income | ||||||||||||||||||||
Operating Income | -50.65M (+4.20%) | -48.61M (-9.93%) | -53.97M (+1.11%) | -53.38M (+1.89%) | -52.39M (+18.48%) | -44.22M (-18.46%) | -54.23M (-2.59%) | -55.67M (+15.16%) | -48.34M (-28.95%) | -68.04M (+32.22%) | -51.46M (+13.70%) | -45.26M (+13.07%) | -40.03M (+3.46%) | -38.69M (+22.24%) | -31.65M (+20.34%) | -26.30M (+32.16%) | -19.90M (-73.13%) | -74.05M (+609.97%) | -10.43M | - |
Ebit | -50.65M (+4.20%) | -48.61M (-9.93%) | -53.97M (+1.11%) | -53.38M (+1.89%) | -52.39M (+18.48%) | -44.22M (-18.46%) | -54.23M (-2.59%) | -55.67M (+15.16%) | -48.34M (-28.95%) | -68.04M (+32.22%) | -51.46M (+13.70%) | -45.26M (+13.07%) | -40.03M (+3.46%) | -38.69M (+22.24%) | -31.65M (+20.34%) | -26.30M (+32.16%) | -19.90M | 12M | -10.43M (-87.96%) | -86.66M |
EBITDA | -48.80M (+4.43%) | -46.73M (-10.29%) | -52.09M (+1.13%) | -51.51M (+1.62%) | -50.69M (+19.27%) | -42.50M (-19.31%) | -52.67M (-2.70%) | -54.13M (+15.10%) | -47.03M (-29.60%) | -66.80M (+33.01%) | -50.22M (+13.77%) | -44.14M (+13.24%) | -38.98M (+3.07%) | -37.82M (+21.92%) | -31.02M (+19.91%) | -25.87M (+31.99%) | -19.60M | 12M | -10.23M (-88.20%) | -86.66M |
Other Income / Expenses | ||||||||||||||||||||
Interest Income | 1.02M (-5.56%) | 1.08M (-5.26%) | 1.14M (+54.05%) | 740K (-37.29%) | 1.18M (-23.38%) | 1.54M (+120.00%) | 700K (+14.75%) | 610K (-10.29%) | 680K (-61.58%) | 1.77M (+331.71%) | 410K (-35.94%) | 640K | - | - | - | - | - | - | - | - |
Net Interest Income | 1.02M (-5.56%) | 1.08M (-5.26%) | 1.14M (+54.05%) | 740K (-37.29%) | 1.18M (-23.38%) | 1.54M (+120.00%) | 700K (+14.75%) | 610K (-10.29%) | 680K (-61.58%) | 1.77M (+331.71%) | 410K (-35.94%) | 640K | - | - | - | - | - | - | - | - |
Other Non Operating Income | 50K (-66.67%) | 150K (+275.00%) | 40K (+100.00%) | 20K (-50.00%) | 40K (0.00%) | 40K | -80.00K | 40K (0.00%) | 40K (-85.19%) | 270K (+575.00%) | 40K (0.00%) | 40K (-98.12%) | 2.13M (+12.11%) | 1.90M (+160.27%) | 730K (+204.17%) | 240K (+2300.00%) | 10K (0.00%) | 10K | - | - |
Net Income | ||||||||||||||||||||
Income Tax Expense | - | - | - | - | - | - | - | -130.00K | 130K | - | -110.00K | 30K | -200.00K (+5.26%) | -190.00K | 210K | -440.00K (-16.98%) | -530.00K | 1.88M | -2.37M | - |
Net Income From Continuing Operations | -49.12M (+6.60%) | -46.08M (-8.90%) | -50.58M (-3.82%) | -52.59M (+1.35%) | -51.89M (+22.73%) | -42.28M (-19.50%) | -52.52M (-5.08%) | -55.33M (+20.91%) | -45.76M (-30.29%) | -65.64M (+29.44%) | -50.71M (+19.66%) | -42.38M (+7.56%) | -39.40M (+0.31%) | -39.28M (+33.83%) | -29.35M (0.00%) | -29.35M (+23.11%) | -23.84M (-62.10%) | -62.91M (+283.36%) | -16.41M (-81.06%) | -86.66M |
Net Income | -49.12M (+6.60%) | -46.08M (-8.90%) | -50.58M (-3.82%) | -52.59M (+1.35%) | -51.89M (+22.73%) | -42.28M (-19.50%) | -52.52M (-5.08%) | -55.33M (+20.91%) | -45.76M (-30.29%) | -65.64M (+29.44%) | -50.71M (+19.66%) | -42.38M (+7.56%) | -39.40M (+0.31%) | -39.28M (+33.83%) | -29.35M (0.00%) | -29.35M (+23.11%) | -23.84M (-62.10%) | -62.91M (+283.36%) | -16.41M (-81.06%) | -86.66M |
Comprehensive Income Net Of Tax | -49.20M (-75.53%) | -201.06M (+297.82%) | -50.54M (-3.90%) | -52.59M (+1.31%) | -51.91M (-73.50%) | -195.87M (+273.58%) | -52.43M (-5.19%) | -55.30M (+20.64%) | -45.84M (-76.82%) | -197.76M (+290.91%) | -50.59M (+19.18%) | -42.45M (+8.24%) | -39.22M (-67.90%) | -122.18M (+312.07%) | -29.65M (+0.61%) | -29.47M (+23.62%) | -23.84M (-85.59%) | -165.39M (+909.09%) | -16.39M | - |